Treating cancer when pRb and p53 cannot be reactivated

Liang Zhu

Research output: Contribution to journalArticle

Abstract

Activation of oncoproteins and inactivation of tumor suppressors induces tumorigenesis. When these events happen upstream of pRb and p53, cancer therapies may initially succeed and then fail when pRb and p53 are activated and then re-inactivated. Therapies might succeed if they remain effective when pRb and p53 are genetically inactivated.

Original languageEnglish (US)
Article numbere1004954
JournalMolecular and Cellular Oncology
Volume2
Issue number4
DOIs
StatePublished - Oct 2 2015

Keywords

  • cancer therapy
  • genetic inactivation
  • miR-17-92
  • p53
  • pRb
  • Skp2

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Treating cancer when pRb and p53 cannot be reactivated'. Together they form a unique fingerprint.

  • Cite this